患有甲状腺功能低下症的患者的治疗偏好
Fabyan Esberard de Lima Beltrão1,2, Giulia Carvalhal3, Daniele Carvalhal de Almeida Beltrão2,4
1Lauro Wanderley University Hospital, Department of Internal Medicine, Federal University of Paraíba, João Pessoa, Paraíba 58050-585, Brazil.
The Journal of clinical endocrinology and metabolism
|September 18, 2024
概括
患有甲状腺功能低下症的患者往往更喜欢组合疗法,包括甲状腺素 (L-T3) 或干燥甲状腺提取物 (DTE),而不是单独治疗甲状腺素 (L-T4). 这种偏好凸显了针对甲状腺功能低下症的个性化治疗决策的重要性.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 利沃甲状腺素 (L-T4) 是甲状腺功能低下症的标准治疗方法.
- 一些患者在L-T4单一治疗中仍然表现出症状,报告了与甲氨酸 (L-T3) 或干燥甲状腺提取物 (DTE) 联合治疗的好处.
研究的目的:
- 评估患者对不同类型甲状腺功能低下症治疗方案的偏好.
- 为了比较患者报告的L-T4单疗法和组合疗法 (L-T4 + L-T3或DTE) 之间的结果.
主要方法:
- 随机对照试验 (RCT) 的系统审查,元分析,元回归和网络元分析.
- 搜索包括到2024年4月10日的PubMed,Embase和Cochrane数据库.
- 数据提取和质量评估由四名独立研究人员进行.
主要成果:
- 分析了11个涉及1135名患者的RCT.
- 52%的患者更喜欢组合治疗 (L-T4 + L-T3或DTE),而24%的人更喜欢L-T4单一治疗.
- 分析证实了对组合治疗的显著偏好 (RR: 2.20; P = .0009),在排除四项研究后,异质性减少 (RR: 1.97; P < .00001).
结论:
- 患有甲状腺功能低下症的患者显然更喜欢组合疗法而不是L-T4单一疗法.
- 这些发现支持将患者偏好纳入低甲状腺症治疗的共享决策.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.3K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.3K
Diabetes: Management and Pharmacotherapy
244
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
244
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Decreased Body Temperature
602
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
602
Psychosis: Goals of Pharmacotherapy
110
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
110
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146


